Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
暂无分享,去创建一个
Glenn J Jaffe | Christian Simader | Ursula Schmidt-Erfurth | Quan Dong Nguyen | Allen C Ho | Oliver Zeitz | Peter K Kaiser | Victor Chong | Olaf Sowade | A. Ho | P. Kaiser | U. Schmidt-Erfurth | J. Slakter | Y. Soo | G. Yancopoulos | N. Stahl | Y. Ogura | J. Korobelnik | Q. Nguyen | C. Simader | G. Jaffe | R. Vitti | J. Heier | David M. Brown | Jeffrey S Heier | David M Brown | Yuichiro Ogura | George D Yancopoulos | Neil Stahl | Robert Vitti | Alyson J Berliner | Yuhwen Soo | Majid Anderesi | Rupert Sandbrink | Jason S Slakter | R. Sandbrink | Jean-François Korobelnik | Christiane Norenberg | Alyson J. Berliner | O. Zeitz | V. Chong | O. Sowade | Christiane Norenberg | Majid Anderesi | Q. Nguyen
[1] Jiayan Huang,et al. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). , 2014, JAMA ophthalmology.
[2] Christian Simader,et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.
[3] G. Ying,et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡* , 2012 .
[4] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[5] W. Freeman,et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.
[6] G. Yancopoulos,et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.
[7] P. Rosenfeld,et al. PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE) , 2011, Retina.
[8] N. Bressler,et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. , 2011, Archives of ophthalmology.
[9] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[10] U. Schmidt-Erfurth,et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.
[11] C. Regillo,et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.
[12] K. Freund,et al. LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED “TREAT AND EXTEND” DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2010, Retina.
[13] Sumit Sharma,et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. , 2009, Ophthalmology.
[14] G. Quentel,et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. , 2009, American journal of ophthalmology.
[15] C. Regillo,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.
[16] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[17] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[18] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[19] R. Klein,et al. Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.
[20] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] Philip J Rosenfeld,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.
[22] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .